10-K: Castle Biosciences Reports 2025 Net Loss Amid Strategic Shifts

Castle Biosciences reported a net loss of $24.2 million in 2025, a significant reversal from the prior year's profit, despite a 3.7% increase in total net revenues driven by non-dermatologic tests.

Summary

• Net revenues for the year ended December 31, 2025, increased by 3.7% to $344.2 million, up from $332.1 million in 2024.
• The company reported a net loss of $24.2 million in 2025, a substantial decline from a net income of $18.2 million in 2024.
• Operating loss for 2025 was $42.8 million, compared to an operating income of $8.7 million in 2024.
• Gross margin percentage decreased to 69.2% in 2025 from 78.5% in 2024, primarily due to lower average selling price (ASP) for DecisionDx-SCC and accelerated amortization of the IDgenetix test.
• Dermatologic test revenue decreased by $40.6 million, while non-dermatologic test revenue increased by $52.8 million, largely driven by an 86.2% increase in TissueCypher test report volumes.
• Total test reports delivered increased to 105,053 in 2025 from 96,071 in 2024.
• The IDgenetix test was discontinued in May 2025, leading to an acceleration of amortization expense of approximately $20.1 million.
• Medicare coverage for the DecisionDx-SCC test was discontinued by Novitas effective April 24, 2025, and by Palmetto/Noridian effective August 18, 2024, impacting 2025 revenues.
• DecisionDx-Melanoma received FDA Breakthrough Device designation in July 2025.
• The company acquired Previse in May 2025, expanding its gastrointestinal diagnostic offerings, and entered a collaboration with SciBase Holding AB in June 2025 for atopic dermatitis diagnostic tests.
• A limited access launch of the AdvanceAD-Tx test for atopic dermatitis commenced in November 2025, with phased expansion planned for 2026.
• Cash and cash equivalents were $116.7 million as of December 31, 2025, with marketable investment securities totaling $182.8 million.
• Net cash provided by operating activities was $64.3 million in 2025, a slight decrease from $64.9 million in 2024.
• Capital expenditures for property and equipment increased to $36.0 million in 2025, primarily due to the new corporate headquarters construction, which was completed in January 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative filing. While revenue growth and strategic expansions are positive, the significant shift from net income to a substantial net loss, coupled with a declining gross margin and the loss of Medicare coverage for a key product, indicates considerable financial headwinds and operational challenges in 2025.

Positives

• Total net revenues increased by 3.7% to $344.2 million in 2025, demonstrating overall business growth.
• Non-dermatologic test revenue saw a significant increase of $52.8 million, primarily from an 86.2% rise in TissueCypher test report volumes.
• Total test reports delivered grew to 105,053 in 2025, indicating increased adoption of the company's diagnostic tests.
• DecisionDx-Melanoma received FDA Breakthrough Device designation in July 2025, highlighting its potential to improve melanoma care.
• The company expanded its portfolio through the acquisition of Previse in May 2025, adding complementary methylation-based intellectual property and a non-endoscopic cell-collection technology.
• A collaboration and license agreement with SciBase Holding AB was established in June 2025 to develop diagnostic tests for dermatologic diseases, starting with atopic dermatitis.
• The AdvanceAD-Tx test for moderate-to-severe atopic dermatitis commenced a limited access launch in November 2025, with plans for phased expansion in 2026, targeting an estimated U.S. TAM of $33 billion.
• The company's new corporate headquarters construction was completed in January 2026, providing expanded facilities.
• The Consolidated Appropriations Act of 2026 delayed Medicare CLFS cuts until 2027, providing temporary relief from potential reimbursement reductions.

Negatives

• The company incurred a net loss of $24.2 million in 2025, a significant reversal from the $18.2 million net income in 2024.
• Operating results shifted from an income of $8.7 million in 2024 to a loss of $42.8 million in 2025.
• Gross margin percentage declined by 9.3% to 69.2% in 2025, primarily due to lower ASP for DecisionDx-SCC and higher amortization expenses.
• Dermatologic test revenue decreased by $40.6 million in 2025, largely due to the loss of Medicare coverage for DecisionDx-SCC.
• The IDgenetix test was discontinued in May 2025, resulting in an accelerated amortization expense of $20.1 million.
• Medicare coverage for DecisionDx-SCC was finalized as non-covered by Novitas (effective April 24, 2025) and Palmetto/Noridian (effective August 18, 2024), which is expected to continue to adversely impact future results.
• The company has an accumulated deficit of $224.3 million as of December 31, 2025, indicating a history of losses.
• A subpoena was received from the U.S. Department of Health and Human Services, Office of Inspector General, in February 2024, seeking documents related to claims submitted for federal healthcare programs, which could be costly and divert management attention.

Risks

• A significant portion of revenue comes from a small number of third-party payors (44% from Medicare, 16% from one commercial payor in 2025).
• Revenue recognition is complex and subject to significant estimation uncertainty, potentially causing fluctuations in reported results.
• The company has incurred significant losses in the past and may be unable to sustain profitability in the future, with an accumulated deficit of $224.3 million.
• Quarterly and annual operating results and cash flows may fluctuate, potentially causing stock price decline.
• Internal control over financial reporting may not be effective, leading to inaccurate financial reports or untimely filings.
• The company may need to raise additional capital to fund operations, commercialize new products, or expand, which could dilute ownership or impose restrictive covenants.
• Revenue depends primarily on sales from DecisionDx-Melanoma, TissueCypher, and DecisionDx-SCC, and the loss of Medicare coverage for DecisionDx-SCC significantly impacts revenue.
• Unfavorable U.S. and global economic conditions (geopolitical conflicts, inflation, supply chain disruptions, bank failures) could adversely affect business.
• Billing for products is complex, time-consuming, and requires substantial resources, with risks of payment delays, denials, and audits.
• Reliance on third parties for sample collection, preparation, and delivery introduces risks of errors or delays.
• Depletion or loss of the sample database could harm product development and improvement.
• Damage or inoperability of primary clinical laboratory facilities could jeopardize testing and R&D efforts.
• New product development is lengthy, complex, and may not result in timely commercialization or reimbursement.
• Products may not achieve or maintain significant commercial market acceptance due to reliance on traditional criteria or lack of guideline inclusion.
• Reliance on limited or sole suppliers for reagents and equipment poses supply chain risks.
• Estimates of Total Addressable Market (TAM) for products may be smaller than projected.
• The diagnostic testing industry is subject to rapid change, potentially rendering current or future products obsolete.
• Limited reimbursement coverage from third-party payors could negatively affect commercial success and revenue.
• Changes in regulations or FDA enforcement discretion for Laboratory Developed Tests (LDTs) could adversely affect the business, potentially requiring extensive regulatory requirements or clinical trials.
• Failure to comply with federal, state, and foreign laboratory licensing requirements could lead to loss of ability to perform tests or sanctions.
• Interim, topline, and preliminary data from clinical studies may change, potentially harming reputation and marketing efforts.
• Changes in healthcare policy could increase costs, decrease revenues, and impact sales and reimbursement.
• Inability to obtain and maintain sufficient intellectual property protection could allow competitors to commercialize similar tests.
• Commercial success depends on operating without infringing third-party intellectual property rights, with risks of litigation.
• Dependence on third-party information technology systems, with risks of system failure or loss of licenses.
• High dependence on key personnel, including the President and CEO, with risks of departure or difficulty in retention.
• Risk of misconduct or improper activities by employees, clinical investigators, consultants, speakers, vendors, and partners.
• Strategic transactions like acquisitions could be disruptive, divert management attention, and impact liquidity and financial results.
• Product or professional liability lawsuits could result in substantial liabilities and limit commercialization.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Requirements associated with being a public company, including loss of smaller reporting company status, increase costs and divert resources.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Inflationary pressures, particularly on personnel and lab supplies, could adversely impact business and financial results.
• Natural disasters, public health crises, and other events beyond control could disrupt business operations.
• The price of common stock may be volatile or decline regardless of operating performance.
• Substantial sales of common stock could cause the price to decline.
• Broad discretion in the use of working capital may not effectively increase share price.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price and trading volume to decline.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Related party transactions create conflicts of interest or the appearance thereof, potentially harming business and stock price.
• The company does not intend to pay dividends for the foreseeable future.
• Concentration of stock ownership limits the ability to influence corporate matters.
• Delaware law and corporate provisions could make a merger, tender offer, or proxy contest difficult.
• The exclusive forum provision in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company anticipates continued investment in commercialization of existing products and development of pipeline candidates. It expects R&D expenses to increase and aims to achieve broad coverage and adequate reimbursement for its products. The phased expansion of AdvanceAD-Tx is planned throughout 2026. The company believes existing cash, marketable securities, and anticipated sales will fund operations for at least the next 12 months, but acknowledges that future funding requirements are uncertain and may necessitate additional equity or debt financings.

Management Comments

• Our vision is to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.
• We continue to believe that changes in FDA's regulatory approach to LDTs will have no material impact on our existing test offerings.
• We believe this designation (FDA Breakthrough Device for DecisionDx-Melanoma) highlights the test's potential to improve melanoma care through individualized prognostic insights.
• We expect to continue pursuing pipeline initiatives for tests that will complement and expand our test offerings.
• We believe that our long-term commercial success, and ability to generate revenue, will depend on our ability to develop and market additional products, on our ability to increase market penetration for our existing and potential future products and on our ability to obtain favorable coverage and reimbursement policies from government payors, such as Medicare, and from private payors, such as insurance companies.

Industry Context

StockSavvy.ai notes that Castle Biosciences operates in a highly dynamic molecular diagnostics industry characterized by rapid technological advancements and evolving regulatory landscapes. The company's strategic acquisitions (Previse) and collaborations (SciBase) reflect a broader industry trend towards expanding test portfolios and leveraging new technologies like spatialomics and AI to address unmet clinical needs. The FDA's vacating and rescinding of the LDT final rule introduces continued regulatory uncertainty for the entire LDT sector, which could impact all players. The company's focus on generating robust clinical evidence and securing reimbursement aligns with industry best practices for gaining market acceptance and financial success in a competitive environment where payors demand strong value propositions. The entry into the atopic dermatitis market with AdvanceAD-Tx positions the company in a large, growing segment of inflammatory skin conditions, diversifying beyond its core cancer diagnostics.

Comparison to Industry Standards

• The company's gross margin of 69.2% in 2025, while a decrease from 2024, remains competitive within the specialized diagnostic testing sector, though specific direct comparisons to competitors like Interpace Diagnostics or SkylineDx are not provided in the filing.
• The increase in TissueCypher test report volumes by 86.2% suggests strong market penetration and adoption for this specific test, potentially outperforming general growth rates in the Barrett's Esophagus diagnostic market.
• The FDA Breakthrough Device designation for DecisionDx-Melanoma places it among a select group of innovative medical devices recognized for their potential to offer more effective diagnosis or treatment of life-threatening conditions, indicating a high standard of clinical innovation.
• The company's employee engagement score of 83% is 11% higher than the healthcare benchmark average for similar surveys in 2025, suggesting strong internal culture and employee satisfaction compared to industry peers.

Corporate Governance

Legal Proceedings

• On February 1, 2024, the company received a subpoena from the U.S. Department of Health and Human Services, Office of Inspector General, seeking documents and information concerning claims submitted for payment under federal healthcare programs from January 1, 2015, through the subpoena date. The company is cooperating with the request, but the outcome is unpredictable, and it could lead to significant liability and reputational harm.

Related Party Transactions

• The company employs three children, a son-in-law, and a brother-in-law of Derek J. Maetzold (President and CEO), two children and a son-in-law of Kristen M. Oelschlager (Chief Operating Officer), and the son of Tobin W. Juvenal (Chief Commercial Officer), all in non-officer positions. These arrangements are subject to the company's related party transactions policy.

Stakeholder Impact

• Shareholders: Experienced a significant net loss and decline in gross margin, potentially impacting stock price. Future capital raises could lead to dilution. Officer trading plans indicate potential future stock sales.
• Employees: Headcount increased by 16% in 2025, and the company maintains competitive compensation and benefits. High employee engagement score (83%) suggests positive workplace environment. However, the discontinuation of IDgenetix may have impacted employees associated with that product line.
• Customers (Clinicians/Patients): New product launches (AdvanceAD-Tx) and acquisitions (Previse) aim to expand diagnostic offerings and improve patient care. Loss of Medicare coverage for DecisionDx-SCC may affect access and cost for some patients.
• Suppliers/Vendors: Reliance on limited or sole suppliers for certain materials poses risks to operations and timely test delivery.
• Regulatory Bodies: Subject to ongoing scrutiny from federal and state healthcare regulatory agencies, including a subpoena from HHS OIG, which could lead to penalties or operational changes.

Next Steps

• Expand availability of the AdvanceAD-Tx test in a phased manner throughout 2026.
• Continue pursuing pipeline initiatives for tests that will complement and expand test offerings.
• Continue to educate physicians and pathologists about the benefits and cost-effectiveness of products through published papers, scientific conferences, and direct marketing.
• Work to obtain favorable coverage and reimbursement policies from government and private payors for existing and future products.
• Continue to cooperate with the U.S. Department of Health and Human Services, Office of Inspector General, in responding to the subpoena.
• Monitor the impact of macroeconomic factors on operational performance and financial condition.
• Evaluate the impact of new accounting pronouncements (ASU 2024-03 and ASU 2025-05) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company's shift from net income to a significant net loss in 2025, coupled with a notable decline in gross margin and the loss of Medicare coverage for DecisionDx-SCC, presents immediate financial concerns. While strategic initiatives like the launch of AdvanceAD-Tx and the acquisition of Previse offer long-term growth potential and diversification, their impact on profitability is yet to be fully realized. The ongoing HHS OIG subpoena adds a layer of uncertainty. Given the mixed financial performance and strategic developments, a 'hold' recommendation is appropriate, suggesting investors monitor the successful integration of new acquisitions, the expansion of new product lines, and the resolution of reimbursement challenges and legal proceedings before making further investment decisions.

Keywords

Molecular Diagnostics, Dermatologic Cancers, Barrett's Esophagus, Atopic Dermatitis, Uveal Melanoma, Gene Expression Profile, GEP Test, TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, AdvanceAD-Tx, MyPath Melanoma, DecisionDx-UM, SEC Filing, 10-K, Financial Results, Reimbursement, Medicare Coverage, FDA Breakthrough Device, LDT Regulation, Acquisitions, Clinical Trials, Intellectual Property, Healthcare Industry